XCUR
Exicure Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
exicure, formerly aurasense therapeutics, is developing a new class of immunomodulatory and gene silencing drugs against validated targets. our 3-dimensional, spherical nucleic acid (sna™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. our lead programs address diseases from inflammatory disorders to oncology. sna constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. sna constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. moreover, snas can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
Market Cap: 5.72 Million
Primary Exchange: NASDAQ
Website: http://www.exicuretx.com/
Shares Outstanding: 8.65 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.3727020555352264
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Ethical Flags
Longest drawdown: 505 trading days
From: 2019-12-12 To: 2024-03-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|